UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

8 Jan 2024

UCB announces European Commission approval of RYSTIGGO[®]▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe

Read More
27 Dec 2023

BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Read More
4 Dec 2023

UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis

Read More
1 Dec 2023

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Read More
23 Nov 2023

Transparency notification Wellington

Read More
16 Nov 2023

‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements

Read More

Stay up-to-date on the latest news and information from UCB